Table 2.
Patient characteristics
| Parameters | NB-2004 (n = 50) |
NB-2009 (n = 54) |
P value |
|---|---|---|---|
| Age (months) | 37 (4–129) | 30.5 (1–231) | 0.460 |
| Age >18 months, n (%) | 42 (84.0) | 45 (83.3) | 0.927 |
| INSS stage, n (%) | 0.116 | ||
| Stage 3 | 5 (10.0) | 2 (3.7) | |
| Stage 4 | 45 (90.0) | 49 (90.7) | |
| Stage 4S | 0 (0.0) | 3 (5.6) | |
| MYCN amplification, n (%) | 22 (44.0) | 25 (48.1) | 0.680 |
| Unfavorable pathology (INPC), n (%) | 37/43 (86.0) | 39/52 (75.0) | 0.180 |
| Serum LDH (IU/L), median (range) | 1766 (505–15 720) | 1746 (416–14 435) | 0.542 |
| Serum ferritin (ng/mL), median (range) | 226 (20–3 284) | 266 (25–1491) | 0.972 |
| Serum NSE (ng/mL), median (range) | 141.2 (17.9–1 507.1) | 97.6 (10.3–1 815.0) | 0.134 |
| 24-h urine VMA (mg), median (range) | 15.0 (0.7–100.0) | 9.3 (0.4–92.4) | 0.576 |
Abbreviations: INSS International Neuroblastoma Staging System, INPC International Neuroblastoma Pathology Classification, LDH lactate dehydrogenase, NSE neuron-specific enolase, VMA vanillylmandelic acid